Genomtec S.A. (WSE:GMT)

Market Cap	93.66M
Revenue (ttm)	6.00K
Net Income (ttm)	-11.76M
Shares Out	14.87M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,372
Average Volume	15,571
Open	6.35
Previous Close	6.30
Day's Range	6.18 - 6.35
52-Week Range	6.01 - 9.70
Beta	0.19
RSI	40.60
Earnings Date	Aug 28, 2025

About Turnstone Biologics

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 26
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GMT

Financial Performance

In 2024, Genomtec's revenue was 1,000, a change of 0.00% compared to the previous year's 1,000. Losses were -11.21 million, 24.4% more than in 2023.